{"mainPropery":{"diseaseId":10335,"diseaseName":"Mucopolysaccharidosis type I","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10335/mucopolysaccharidosis-type-i","synonyms":["MPS 1","Attenuated MPS I (subtype, includes Hurler-Scheie and Scheie syndrome)","Severe MPS I (subtype, also known as Hurler syndrome)","Hurler syndrome (subtype)","Hurler-Scheie syndrome (subtype)","Scheie syndrome (subtype) formerly known as Mucopolysaccharidosis type V)","Alpha-L-Iduronidase deficiency","IDUA deficiency","MPS I"],"synonyms-with-source":[{"name":"MPS 1"},{"name":"Attenuated MPS I (subtype, includes Hurler-Scheie and Scheie syndrome)","source":"Orphanet"},{"name":"Severe MPS I (subtype, also known as Hurler syndrome)","source":""},{"name":"Hurler syndrome (subtype)","source":"Orphanet"},{"name":"Hurler-Scheie syndrome (subtype)","source":"Orphanet"},{"name":"Scheie syndrome (subtype) formerly known as Mucopolysaccharidosis type V)","source":"Orphanet & OMIM"},{"name":"Alpha-L-Iduronidase deficiency"},{"name":"IDUA deficiency"},{"name":"MPS I"}],"identifiers":[{"identifierType":"OMIM","identifierId":"607015"},{"identifierType":"ORPHANET","identifierId":"579"}]},"diseaseCategories":[{"diseaseTypeId":37,"diseaseTypeName":"Newborn Screening"}],"organizations":[{"resourceID":37,"resourceName":"Canadian Society for Mucopolysaccharide and Related Diseases Inc. (Canadian MPS Society)","abbreviation":"","address1":"#218-2055 Commercial Drive ","address2":"Vancouver, BC V5N OC7","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"Canada","phone":"604-924-5130","tty":"","tollFree":"800-667-1846","fax":"604-924-5131","email":"info@mpssociety.ca","url":"http://www.mpssociety.ca","freeText":""},{"resourceID":209,"resourceName":"National MPS Society","abbreviation":"","address1":"P.O. Box 14686 ","address2":"","address3":"","address4":"","address5":"","city":"Durham","state":"NC","zip":"27709-4686","country":"United States","phone":"+1-919-806-0101","tty":"","tollFree":"1-877-MPS-1001 (1-877-677-1001)","fax":"+1-919-806-2055","email":"info@mpssociety.org","url":"https://mpssociety.org/","freeText":""},{"resourceID":210,"resourceName":"Society for Mucopolysaccharide (MPS) Diseases","abbreviation":"","address1":"MPS House Repton Place White Lion Road","address2":"Amersham Buckinghamshire","address3":"HP7 9LP","address4":"","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"(+44) 0345 389 9901 ","tty":"","tollFree":"","fax":"","email":"mps@mpssociety.co.uk","url":"http://www.mpssociety.co.uk","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/607015' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(%22mucopolysaccharidosis+i%22%5BMeSH+Terms%5D+OR+%22mucopolysaccharidosis+i%22%5BAll+Fields%5D+OR+%22mucopolysaccharidosis+type+i%22%5BAll+Fields%5D)+AND+(hasabstract%5Btext%5D+AND+%222006%2F07%2F17%22%5BPDat%5D+%3A+%222008%2F07%2F15%22%5BPDat%5D+AND+%22humans%22%5BMeSH+Terms%5D+AND+English%5Blang%5D)' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Mucopolysaccharidosis type I. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Mucopolysaccharidosis+type+I%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Mucopolysaccharidosis type I. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":267,"resourceId":1104,"resourceName":"American Society of Gene & Cell Therapy -Disease treatment","descriptionText":"The <a href='https://www.asgct.org/education' target='_blank'>American Society of Gene &amp; Cell Therapy</a> provides information on the treatment of genetic diseases.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":350,"resourceId":1167,"resourceName":"Baby's First Test","descriptionText":"<a href='https://www.babysfirsttest.org/newborn-screening/conditions/mucopolysaccharidosis-type-i' target='_blank'>Baby's First Test</a> is the nation's newborn screening education center for families and providers. This site provides information and resources about screening at the local, state, and national levels and serves as the Clearinghouse for newborn screening information.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Newborn Screening"},{"id":869,"resourceId":1575,"resourceName":"RDCRN - Lysosomal Disease Network","descriptionText":"The&nbsp;<a href='https://www.rarediseasesnetwork.org/ldn' target='_blank'>Lysosomal Disease Network</a>&nbsp;is a team of doctors, nurses, research coordinators, and research labs throughout the U.S., working together to improve the lives of people with this condition through research. The&nbsp;Lysosomal Disease Network&nbsp;has a registry for patients who wish to be contacted about clinical research opportunities.<br />","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='https://rarediseases.org/rare-diseases/mucopolysaccharidosis-type-i/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001204.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/All-Disorders/Mucopolysaccharidoses-Information-Page' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022415' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=579' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=mps1' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1833,"resourceId":3029,"resourceName":"Article - Long-Term Functional Outcomes of Children with Hurler Syndrome Treated with Unrelated Umbilical Cord Blood Transplantation","descriptionText":"Coletti HY, Aldenhoven M, Yelin K, Poe MD, Kurtzberg J, and Escolar ML. <a href='http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375128/' target='_blank'>Long-Term Functional Outcomes of Children with Hurler Syndrome Treated with Unrelated Umbilical Cord Blood Transplantation</a> JIMD Rep. 2015; 20: 77&ndash;86.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"},{"id":2010,"resourceId":3238,"resourceName":"Orphan Disease Center: MPS I Pilot Grant Program","descriptionText":"The <a target=\"_blank\" href=\"http://www.med.upenn.edu/orphandisease/rare-disease-overview.shtml#MPSI \">Orphan Disease Center: MPS I Pilot Grant Program</a> presents a request for applications (RFA) to support research on the development of improved therapies for people with syndromes due to MPS I including Hurler, Hurler-Scheie and Scheie. All individuals holding a faculty-level appointment at an academic or non-profit institution are eligible to respond to this RFA. Grants will be awarded for an initial period of 1 to 2 years at $150,000 direct costs per year (up to 10% indirect costs allowable); funding for a second year is predicated by adequate progress during year 1 and availability of funding. All applicants must first submit a letter of Interest (LOI) to be reviewed for consideration of a full application submission. LOIs are due no later than Monday, February 29, 2016 at 5pm (EST).","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:12802' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":904,"questionText":"What is mucopolysaccharidosis I?","answerText":"<strong>Mucopolysaccharidosis type I (MPS I)</strong> is a condition that affects many parts of the body. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.&nbsp;MPS I&nbsp;is caused by mutations in the <em><a href=\"http://ghr.nlm.nih.gov/gene/IDUA\" target=\"_blank\">IDUA</a></em> gene. These mutations lead to reduced levels or the complete lack of&nbsp;the IDUA <a href=\"http://www.genome.gov/glossary.cfm?key=enzyme\" target=\"_blank\">enzyme</a>. Without the proper amount of this enzyme, large sugar molecules called glycosaminoglycans (GAGs) accumulate within cells called lysosomes. This causes the lysosomes to increase in size, causing many different&nbsp;organs and tissues of the body to become enlarged. This leads to the medical problems seen in the condition.[558][10556]&nbsp;<br />\r\n<br />\r\nMPS I was once divided into three separate syndromes: Hurler syndrome, Hurler-Scheie syndrome, and Scheie syndrome, listed from most to least severe. Because no biochemical differences have been identified and the clinical findings overlap, the condition is now divided into two subtypes, severe MPS I and attenuated MPS I.[558][10556] People with severe MPS I typically have an earlier onset of symptoms, a decline in intellectual function, and a shorter lifespan. Although there is no cure for MPS I,&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">bone marrow transplant</a> and enzyme replacement therapy are treatment options that may help manage the symptoms of this condition.[558]","dateModified":"2016-02-03T00:00:00"},"basicQuestions":[{"questionId":905,"questionText":"What are the symptoms of mucopolysaccharidosis I?","answerText":"The signs and symptoms of&nbsp;mucopolysaccharidosis type I (MPS I) are not present at birth, but they begin to appear during childhood. People with severe MPS I develop the features of this condition earlier than those with attenuated MPS I. The following list includes the most common signs and symptoms of MPS I:[558]\r\n<ul>\r\n    <li>Enlarged&nbsp;head, lips, cheeks, tongue, and nose\r\n    </li>\r\n    <li>Enlarged&nbsp;vocal cords, resulting in a deep voice\r\n    </li>\r\n    <li>Frequent upper respiratory infections\r\n    </li>\r\n    <li><a href=\"http://www.nhlbi.nih.gov/health/dci/Diseases/SleepApnea/SleepApnea_WhatIs.html\" target=\"_blank\">Sleep apnea</a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/hydrocephalus/detail_hydrocephalus.htm\" target=\"_blank\">Hydrocephalus</a>\r\n    </li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/imagepages/17215.htm\" target=\"_blank\">Hepatosplenomegaly</a>&nbsp;(enlarged liver and spleen)\r\n    </li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000987.htm\" target=\"_blank\">Umbilical hernia </a>\r\n    </li>\r\n    <li><a href=\"http://digestive.niddk.nih.gov/ddiseases/pubs/inguinalhernia/\" target=\"_blank\">Inguinal hernia </a>\r\n    </li>\r\n    <li>Hearing loss\r\n    </li>\r\n    <li>Recurrent ear infections&nbsp;\r\n    </li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003317.htm\" target=\"_blank\">Corneal clouding</a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/carpal_tunnel/detail_carpal_tunnel.htm\" target=\"_blank\">Carpal tunnel syndrome</a>\r\n    </li>\r\n    <li>Narrowing of the spinal canal (spinal stenosis)\r\n    </li>\r\n    <li>Heart valve abnormalities, which can lead to heart failure\r\n    </li>\r\n    <li>Short stature\r\n    </li>\r\n    <li>Joint deformities (contractures)\r\n    </li>\r\n    <li>Dysostosis multiplex (generalized thickening of most long bones, particularly the ribs)</li>\r\n    <li>Developmental delays and regression&nbsp;</li>\r\n</ul>","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":907,"questionText":"What causes mucopolysaccharidosis I?","answerText":"<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">Mutations</a>  in the <em><a href=\"https://ghr.nlm.nih.gov/gene/IDUA\" target=\"_blank\">IDUA</a></em> <a href=\"http://www.genome.gov/glossary.cfm?key=gene\" target=\"_blank\">gene </a>cause mucopolysaccharidosis type I (MPS I). The <em>IDUA</em> gene provides instructions for producing an enzyme (alpha-L-iduronidase) that is involved in the breakdown of large sugar molecules called <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002263.htm\">glycosaminoglycans </a>(GAGs). Mutations in the <em>IDUA </em>gene reduce or completely eliminate the function of alpha-L-iduronidase. This  leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions that cause molecules to build up inside the lysosomes, including MPS I, are called <a href=\"http://www.merck.com/mmpe/sec19/ch296/ch296f.html\" target=\"_blank\">lysosomal storage disorders</a>. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder.[558][11548]","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11548,"authors":"","articleTitle":"IDUA","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May 17, 2016","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/gene/IDUA","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":908,"questionText":"How is mucopolysaccharidosis I inherited?","answerText":"Mucopolysaccharidosis type I (MPS I) is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>  manner.[558] This means that to be affected, a person must have a mutation in both copies of the responsible gene in each cell. Affected people inherit one mutated copy of the gene from each parent, who is referred to as a carrier. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:<br />\r\n<ul>\r\n    <li>25% (1 in 4) chance to be affected</li>\r\n    <li>50% (1 in 2) chance to be an unaffected carrier like each parent</li>\r\n    <li>25% chance to be unaffected and not be a carrier</li>\r\n</ul>\r\nIf you are concerned about your risks to be a carrier of MPS I, we would recommend you consult with a genetics specialist, such as a <a href=\"http://www.ashg.org/education/careers.shtml\" target=\"_blank\">geneticist</a> or a <a href=\"http://www.nlm.nih.gov/medlineplus/geneticcounseling.html\" target=\"_blank\">genetic counselor</a>. See our page on <a href=\"https://rarediseases.info.nih.gov/resources/pages/25/how-to-find-a-disease-specialist#Question3\" target=\"_blank\">how to find a genetics clinic</a> to identify a local genetics specialist. &nbsp;","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":909,"questionText":"How might mucopolysaccharidosis I be treated?","answerText":"Management of mucopolysaccharidosis type I (MPS I) requires a multidisciplinary team given the wide range of <a href=\"https://rarediseases.info.nih.gov/gard/10335/mucopolysaccharidosis-type-i/resources/9\" target=\"_blank\">symptoms</a>. This team may include: primary care; cardiology; pulmonology; gastroenterology; neurology; ear, nose, and throat specialists; audiology; ophthalmology; orthopedics; physical therapy; dental; and developmental specialists.[11552]<br />\r\n<br />\r\nThe two main treatment options for MPS I include <a href=\"http://stemcells.nih.gov/info/scireport/pages/chapter5.aspx\" target=\"_blank\">hematopoietic stem cell transplant</a>&nbsp;(HSCT) and <a href=\"http://mpssociety.org/treatments/treatments-ert/\" target=\"_blank\">enzyme replacement therapy</a> (ERT). Both of these treatments work by replacing the missing IDUA enzyme (alpha-L-iduronidase).[558]<br />\r\n<br />\r\nHSCT is considered standard of care for individuals with severe MPS I; however, its success is dependent on timing of treatment. It is typically recommended that HSCT occur early in the disease process, prior to two years of age. Studies have shown that when successful, HSCT can improve  facial, auditory, and cardiac manifestations. The effect on intellectual development is unclear with some studies suggesting an improvement, while others report a slowing of cognitive decline.[558][11552]<br />\r\n&nbsp;<br />\r\nA drug called <a href=\"http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm083688.pdf\" target=\"_blank\">laronidase</a> or Aldurazyme is the enzyme replacement therapy for MPS I.&nbsp;Treatment with laronidase can improve problems with breathing, growth, the bones, joints and heart. However, this treatment is not expected to&nbsp;treat problems with&nbsp;mental development because laronidase cannot cross the <a href=\"http://www.brainfacts.org/brain-basics/neuroanatomy/articles/2014/blood-brain-barrier\" target=\"_blank\">blood-brain barrier</a>.[558][11552]<br />\r\n<br />","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11552,"authors":"Joseph Muenzer, James E. Wraith, Lorne A. Clarke","articleTitle":"Mucopolysaccharidosis I: Management and Treatment Guidelines","bookWebsiteJournalTitle":"Pediatrics","date":"January 2009","volume":"123(1)","pages":"","url":"http://www.ncbi.nlm.nih.gov/pubmed/19117856","dateAccessed":"2016-05-23T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":12559,"relatedDiseaseName":"Hurler syndrome","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":12560,"relatedDiseaseName":"Hurler–Scheie syndrome ","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":7065,"relatedDiseaseName":"Mucopolysaccharidosis","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":12561,"relatedDiseaseName":"Scheie syndrome ","relation":"Child","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":22031,"abbreviatedInquiry":"I would like general information on&nbsp;mucopolysaccharidosis I&nbsp;(MPS I). My grandson was recently&nbsp;diagnosed&nbsp;with&nbsp;this condition and is currently undergoing enzyme therapy.&nbsp;Is a person with MPS I less likely to have brain damage if a bone marrow transplant is performed early?&nbsp;","caseQuestions":[{"questionId":904,"questionText":"What is mucopolysaccharidosis I?","answerText":"<strong>Mucopolysaccharidosis type I (MPS I)</strong> is a condition that affects many parts of the body. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.&nbsp;MPS I&nbsp;is caused by mutations in the <em><a href=\"http://ghr.nlm.nih.gov/gene/IDUA\" target=\"_blank\">IDUA</a></em> gene. These mutations lead to reduced levels or the complete lack of&nbsp;the IDUA <a href=\"http://www.genome.gov/glossary.cfm?key=enzyme\" target=\"_blank\">enzyme</a>. Without the proper amount of this enzyme, large sugar molecules called glycosaminoglycans (GAGs) accumulate within cells called lysosomes. This causes the lysosomes to increase in size, causing many different&nbsp;organs and tissues of the body to become enlarged. This leads to the medical problems seen in the condition.[558][10556]&nbsp;<br />\r\n<br />\r\nMPS I was once divided into three separate syndromes: Hurler syndrome, Hurler-Scheie syndrome, and Scheie syndrome, listed from most to least severe. Because no biochemical differences have been identified and the clinical findings overlap, the condition is now divided into two subtypes, severe MPS I and attenuated MPS I.[558][10556] People with severe MPS I typically have an earlier onset of symptoms, a decline in intellectual function, and a shorter lifespan. Although there is no cure for MPS I,&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">bone marrow transplant</a> and enzyme replacement therapy are treatment options that may help manage the symptoms of this condition.[558]","dateModified":"2016-02-03T00:00:00","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":10556,"authors":"","articleTitle":"Mucopolysaccharidosis type I","bookWebsiteJournalTitle":"Genetics Home Reference (GHR)","date":"December 2012","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-i","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":905,"questionText":"What are the symptoms of mucopolysaccharidosis I?","answerText":"The signs and symptoms of&nbsp;mucopolysaccharidosis type I (MPS I) are not present at birth, but they begin to appear during childhood. People with severe MPS I develop the features of this condition earlier than those with attenuated MPS I. The following list includes the most common signs and symptoms of MPS I:[558]\r\n<ul>\r\n    <li>Enlarged&nbsp;head, lips, cheeks, tongue, and nose\r\n    </li>\r\n    <li>Enlarged&nbsp;vocal cords, resulting in a deep voice\r\n    </li>\r\n    <li>Frequent upper respiratory infections\r\n    </li>\r\n    <li><a href=\"http://www.nhlbi.nih.gov/health/dci/Diseases/SleepApnea/SleepApnea_WhatIs.html\" target=\"_blank\">Sleep apnea</a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/hydrocephalus/detail_hydrocephalus.htm\" target=\"_blank\">Hydrocephalus</a>\r\n    </li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/imagepages/17215.htm\" target=\"_blank\">Hepatosplenomegaly</a>&nbsp;(enlarged liver and spleen)\r\n    </li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000987.htm\" target=\"_blank\">Umbilical hernia </a>\r\n    </li>\r\n    <li><a href=\"http://digestive.niddk.nih.gov/ddiseases/pubs/inguinalhernia/\" target=\"_blank\">Inguinal hernia </a>\r\n    </li>\r\n    <li>Hearing loss\r\n    </li>\r\n    <li>Recurrent ear infections&nbsp;\r\n    </li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003317.htm\" target=\"_blank\">Corneal clouding</a>\r\n    </li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/carpal_tunnel/detail_carpal_tunnel.htm\" target=\"_blank\">Carpal tunnel syndrome</a>\r\n    </li>\r\n    <li>Narrowing of the spinal canal (spinal stenosis)\r\n    </li>\r\n    <li>Heart valve abnormalities, which can lead to heart failure\r\n    </li>\r\n    <li>Short stature\r\n    </li>\r\n    <li>Joint deformities (contractures)\r\n    </li>\r\n    <li>Dysostosis multiplex (generalized thickening of most long bones, particularly the ribs)</li>\r\n    <li>Developmental delays and regression&nbsp;</li>\r\n</ul>","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":907,"questionText":"What causes mucopolysaccharidosis I?","answerText":"<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">Mutations</a>  in the <em><a href=\"https://ghr.nlm.nih.gov/gene/IDUA\" target=\"_blank\">IDUA</a></em> <a href=\"http://www.genome.gov/glossary.cfm?key=gene\" target=\"_blank\">gene </a>cause mucopolysaccharidosis type I (MPS I). The <em>IDUA</em> gene provides instructions for producing an enzyme (alpha-L-iduronidase) that is involved in the breakdown of large sugar molecules called <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002263.htm\">glycosaminoglycans </a>(GAGs). Mutations in the <em>IDUA </em>gene reduce or completely eliminate the function of alpha-L-iduronidase. This  leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions that cause molecules to build up inside the lysosomes, including MPS I, are called <a href=\"http://www.merck.com/mmpe/sec19/ch296/ch296f.html\" target=\"_blank\">lysosomal storage disorders</a>. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder.[558][11548]","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11548,"authors":"","articleTitle":"IDUA","bookWebsiteJournalTitle":"Genetics Home Reference","date":"May 17, 2016","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/gene/IDUA","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":908,"questionText":"How is mucopolysaccharidosis I inherited?","answerText":"Mucopolysaccharidosis type I (MPS I) is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>  manner.[558] This means that to be affected, a person must have a mutation in both copies of the responsible gene in each cell. Affected people inherit one mutated copy of the gene from each parent, who is referred to as a carrier. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:<br />\r\n<ul>\r\n    <li>25% (1 in 4) chance to be affected</li>\r\n    <li>50% (1 in 2) chance to be an unaffected carrier like each parent</li>\r\n    <li>25% chance to be unaffected and not be a carrier</li>\r\n</ul>\r\nIf you are concerned about your risks to be a carrier of MPS I, we would recommend you consult with a genetics specialist, such as a <a href=\"http://www.ashg.org/education/careers.shtml\" target=\"_blank\">geneticist</a> or a <a href=\"http://www.nlm.nih.gov/medlineplus/geneticcounseling.html\" target=\"_blank\">genetic counselor</a>. See our page on <a href=\"https://rarediseases.info.nih.gov/resources/pages/25/how-to-find-a-disease-specialist#Question3\" target=\"_blank\">how to find a genetics clinic</a> to identify a local genetics specialist. &nbsp;","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":909,"questionText":"How might mucopolysaccharidosis I be treated?","answerText":"Management of mucopolysaccharidosis type I (MPS I) requires a multidisciplinary team given the wide range of <a href=\"https://rarediseases.info.nih.gov/gard/10335/mucopolysaccharidosis-type-i/resources/9\" target=\"_blank\">symptoms</a>. This team may include: primary care; cardiology; pulmonology; gastroenterology; neurology; ear, nose, and throat specialists; audiology; ophthalmology; orthopedics; physical therapy; dental; and developmental specialists.[11552]<br />\r\n<br />\r\nThe two main treatment options for MPS I include <a href=\"http://stemcells.nih.gov/info/scireport/pages/chapter5.aspx\" target=\"_blank\">hematopoietic stem cell transplant</a>&nbsp;(HSCT) and <a href=\"http://mpssociety.org/treatments/treatments-ert/\" target=\"_blank\">enzyme replacement therapy</a> (ERT). Both of these treatments work by replacing the missing IDUA enzyme (alpha-L-iduronidase).[558]<br />\r\n<br />\r\nHSCT is considered standard of care for individuals with severe MPS I; however, its success is dependent on timing of treatment. It is typically recommended that HSCT occur early in the disease process, prior to two years of age. Studies have shown that when successful, HSCT can improve  facial, auditory, and cardiac manifestations. The effect on intellectual development is unclear with some studies suggesting an improvement, while others report a slowing of cognitive decline.[558][11552]<br />\r\n&nbsp;<br />\r\nA drug called <a href=\"http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm083688.pdf\" target=\"_blank\">laronidase</a> or Aldurazyme is the enzyme replacement therapy for MPS I.&nbsp;Treatment with laronidase can improve problems with breathing, growth, the bones, joints and heart. However, this treatment is not expected to&nbsp;treat problems with&nbsp;mental development because laronidase cannot cross the <a href=\"http://www.brainfacts.org/brain-basics/neuroanatomy/articles/2014/blood-brain-barrier\" target=\"_blank\">blood-brain barrier</a>.[558][11552]<br />\r\n<br />","dateModified":"2016-05-23T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":558,"authors":"Clarke LA, Heppner J","articleTitle":"Mucopolysaccharidosis Type I","bookWebsiteJournalTitle":"GeneReviews","date":"February 11, 2016","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1162/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":11552,"authors":"Joseph Muenzer, James E. Wraith, Lorne A. Clarke","articleTitle":"Mucopolysaccharidosis I: Management and Treatment Guidelines","bookWebsiteJournalTitle":"Pediatrics","date":"January 2009","volume":"123(1)","pages":"","url":"http://www.ncbi.nlm.nih.gov/pubmed/19117856","dateAccessed":"2016-05-23T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":912,"questionText":"Is  hematopoietic stem cell transplantation effective in reducing the likelihood of brain damage in individuals with mucopolysaccharidosis type I?&nbsp;","answerText":"While the effect of <a href=\"http://stemcells.nih.gov/info/scireport/pages/chapter5.aspx\" target=\"_blank\">hematopoietic stem cell transplantation</a> (HSCT) on intellectual development in individuals with mucopolysaccharidosis type I (MPS I) remains unclear, studies suggest that there is a lower likelihood of problems with intellectual development if HSCT is performed prior to the onset of neurological symptoms. HSCT has been found to stop the damage caused by MPS I before it becomes severe.  HSCT may not be helpful for all individuals with MPS I. This surgery has serious risks that must be considered before making treatment decisions.[557]","dateModified":"2016-05-23T00:00:00","references":[{"referenceId":557,"authors":"","articleTitle":"Hurler's Syndrome and Transplant","bookWebsiteJournalTitle":"National Marrow Donor Program Web site","date":"","url":"http://www.marrow.org/PATIENT/Undrstnd_Disease_Treat/Lrn_about_Disease/Metabolic_Storage/Hurler_and_Tx/index.html","dateAccessed":"2008-07-15T00:00:00"}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":11001,"phenoTypeName":"Abnormal form of the vertebral bodies","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3469,"phenoTypeName":"Abnormality of epiphysis morphology","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10271,"phenoTypeName":"Abnormality of the metaphysis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":4765,"phenoTypeName":"Abnormality of the voice","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11326,"phenoTypeName":"Chronic otitis media","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9878,"phenoTypeName":"Coarse facial features","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14402,"phenoTypeName":"Corneal opacity","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8104,"phenoTypeName":"Generalized hirsutism","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6359,"phenoTypeName":"Inguinal hernia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5683,"phenoTypeName":"Joint stiffness","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":1363,"phenoTypeName":"Mucopolysacchariduria","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13814,"phenoTypeName":"Scoliosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3605,"phenoTypeName":"Short stature","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9832,"phenoTypeName":"Sinusitis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3066,"phenoTypeName":"Split hand","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9128,"phenoTypeName":"Abnormal nasal morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10964,"phenoTypeName":"Abnormality of the hip bone","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11840,"phenoTypeName":"Abnormality of the tonsils","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13736,"phenoTypeName":"Apnea","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":7919,"phenoTypeName":"Arthralgia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9070,"phenoTypeName":"Cough","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11344,"phenoTypeName":"Depressed nasal bridge","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5154,"phenoTypeName":"Developmental regression","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9864,"phenoTypeName":"Dolichocephaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":114,"phenoTypeName":"Enlarged thorax","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9816,"phenoTypeName":"Everted lower lip vermilion","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9893,"phenoTypeName":"Full cheeks","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14208,"phenoTypeName":"Gingival overgrowth","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5610,"phenoTypeName":"Glaucoma","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8715,"phenoTypeName":"Intellectual disability","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9866,"phenoTypeName":"Low anterior hairline","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9851,"phenoTypeName":"Macrocephaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13413,"phenoTypeName":"Malabsorption","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":12627,"phenoTypeName":"Microdontia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5592,"phenoTypeName":"Paresthesia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8075,"phenoTypeName":"Recurrent respiratory infections","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10492,"phenoTypeName":"Retinopathy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11337,"phenoTypeName":"Sensorineural hearing impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9781,"phenoTypeName":"Thick lower lip vermilion","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":7323,"phenoTypeName":"Thick nasal alae","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":12622,"phenoTypeName":"Widely spaced teeth","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8978,"phenoTypeName":"Abnormal aortic valve morphology","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7749,"phenoTypeName":"Abnormal tendon morphology","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7826,"phenoTypeName":"Avascular necrosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4779,"phenoTypeName":"Congestive heart failure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10332,"phenoTypeName":"Hemiplegia/hemiparesis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9825,"phenoTypeName":"Hydrocephalus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8970,"phenoTypeName":"Hypertrophic cardiomyopathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5673,"phenoTypeName":"Joint dislocation","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5601,"phenoTypeName":"Spinal canal stenosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5614,"phenoTypeName":"Visual impairment","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8989,"phenoTypeName":"Aortic regurgitation","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":10270,"phenoTypeName":"Dysostosis multiplex","percentRanges":"-"},{"phenoTypeId":8284,"phenoTypeName":"Hirsutism","percentRanges":"-"},{"phenoTypeId":7902,"phenoTypeName":"Kyphosis","percentRanges":"-"},{"phenoTypeId":10427,"phenoTypeName":"Micrognathia","percentRanges":"-"},{"phenoTypeId":8979,"phenoTypeName":"Mitral regurgitation","percentRanges":"-"},{"phenoTypeId":7960,"phenoTypeName":"Obstructive sleep apnea","percentRanges":"-"},{"phenoTypeId":13730,"phenoTypeName":"Pulmonary arterial hypertension","percentRanges":"-"},{"phenoTypeId":15422,"phenoTypeName":"Thick vermilion border","percentRanges":"-"},{"phenoTypeId":9339,"phenoTypeName":"Thickened skin","percentRanges":"-"},{"phenoTypeId":10718,"phenoTypeName":"Tracheal stenosis","percentRanges":"-"},{"phenoTypeId":4092,"phenoTypeName":"Umbilical hernia","percentRanges":"-"}],"medicalProducts":[{"productId":71,"genericName":"laronidase","tradeName":"Aldurazyme","tradeLink":"http://www.biomarin.com/products/aldurazyme/","manufacturer":"","sponsor":"BioMarin Pharmaceutical, Inc.","indication":"Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/aldurazyme","medlinePlusLink":""}],"EncodedName":"Mucopolysaccharidosis_type_I"}